Diamyd, with R&D here, inks $625M deal with J&J
Diamyd Medical AB, a Stockholm, Sweden-based company that maintains its research and development facilities in Pittsburgh, secured a major deal with a unit of Johnson & Johnson to develop and commercialize Diamyd's diabetes therapy.
The agreement over time could be worth more than $625 million to Ortho-McNeil-Janssen Pharmaceuticals Inc., the company said.
Diamyd came to Pittsburgh in 2005 when it acquired Nurel Therapeutics, founded by University of Pittsburgh scientists.
Darren Wolfe, CEO of Diamyd Inc. USA, said his R&D unit has more than doubled its work force in the last six months, to seven, and expects to employ 10 to 12 people within a year.
The company is housed within the Pittsburgh Life Sciences Greenhouse incubator at the Pittsburgh Technology Center in South Oakland. The Greenhouse also is an investor in Diamyd, having placed $100,000 in the local operations.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.